Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies
Partnership aims to create recombinant nanobodies to treat immune disorders Grifols, a global healthcare company and leading manufacturer of plasma-derived...
Selected News
Algiax announces results from phase 2a trial for neuropathic pain treatment
Study shows AP-325 offers lasting pain relief without central side effects Algiax Pharmaceuticals, a company committed to developing innovative treatments...
Aplagon secures EUR 7 million for APAC phase 2a trials
Funding led by new investors FSG and EIC Fund Helsinki-based Aplagon has raised EUR 7 million to advance its APAC...
CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients
Positive opinion issued for marketing authorisation extension The Committee for Medicinal Products for Human Use (CHMP) has recommended extending marketing...
Cartesian Therapeutics announces FDA agreement for new trial
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the...
FDA approves new Alzheimer’s treatment regimen
Patients and care partners may find once every four weeks maintenance dosing easier The US Food and Drug Administration (FDA)...
![[Charania] Milwaukee Bucks: Damian Lillard has sustained a deep vein thrombosis (blood clot) in his right calf. Lillard is on blood-thinning medication, which has stabilized the blood clot, and will continue with regular testing. He is out indefinite peri](https://i0.wp.com/www.phamed.com/wp-content/uploads/2025/03/1628493-charania-milwaukee-bucks-damian-lillard-has-sustained-a-deep-vein-thrombosis-blood-clot-in67e3969544bc3.jpg?fit=300%2C300&ssl=1)
